<prompt> Abciximab isAntithrombin III inhibitorGp IIbIIIa antibodyAlanine analogueP2YAC Purine receptor antagonist  <response>: Ans. b Gp IIbIIIa antibody Ref. KDT 6th Table 112-1- Abciximab is antiplatelet drug which is Gp IlbIIIa antagonist.GPIIb IIIa AntagonistsFeatureAbciximabEptifibatideTirofibanDescriptionFab fragment of humanized mouse monoclonal antibodyCyclical KGD-containing heptapeptideNonpeptidic RGD mimeticSpecific for GPIIbIIIaNoYesYesPlasma half-lifeShort minLong 2.5 hLong 2.0 hPlatelet-bound half-lifeLong daysShort secShort secRenal clearanceNoYesYes- Other Antithrombotic Drugs are: ANTITHROMBOTIC DRUGS: Antiplatelet drugsAnticoagulantsDirect thrombin inhibitorsFibrinolyticsAspirinHeparinArgatrobanStreptokinaseThienopyridinesLMWHLepirudin Anistreplaseclopidogrelticlopidine,Fondaparinux,Bivalirudin rt-PA alteplaseDipyridimole, andWarfarin TenecteplaseGPIIbllla antagonists.warfarin is only available oral anticoag ReteplaseDesmoteplase AlfimepraseLMWH and Fondaparinux, ComparisonFeaturesLMWHFondaparinuxNumber of saccharide units15-175Catalysis of factor Xa inhibitionYesYesCatalysis of thrombin inhibitionYesNoBioavailability after subcutaneous administration 90100Plasma half-life h417Renal excretionYesYesInduces release of tissue factor pathway inhibitorYesNoNeutralized by protamine sulfatePartiallyNoHirudin, Bivalirudinand Argatroban, Comparison. HirudinBivalirudinArgatrobanMolecular mass70001980527Interaction Site with thrombinActive site and exosite 1Active site and exosite 1Active siteRenal clearanceYesNoNoHepatic metabolismNoNoYesPlasma half-life min602545 